Krystal Biotech (NASDAQ:KRYS) said it has generated positive interim clinical results for its inhaled cystic fibrosis (CF) ...

Confirmed wild-type CFTR delivery and expression in conducting airway cells of patients with class I mutationsKB407 transduction confirmed in all ...

Confirmed wild-type CFTR delivery and expression in conducting airway cells of patients with class I mutations KB407 transduction confirmed in all six patients with successful bronchoscopies irrespect ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced business and program updates ahead of upcoming investor ...

The cost of medication was too high for thousands of CF sufferers around the world. Now a Bangladeshi company is making a generic version that will change lives ...

Detailed price information for Krystal Biotech Inc (KRYS-Q) from The Globe and Mail including charting and trades.

A live webcast of the presentation will be available under the “Events” page within the Investors section of Sionna’s website ...

Detailed price information for Amicus Therapeutics (FOLD-Q) from The Globe and Mail including charting and trades.

Krystal Biotech is upgraded to Strong Buy as Vyjuvek sales surge and catalysts build. Click here to know more.

Moderna stock soared in the early stages of the pandemic, then struggled -- but in recent times, it’s been on the rise. This other biotech has proven itself as a long-term winner. 10 stocks we like ...

Vertex on track for “five launches in five disease areas over a five-year period” through emerging pain and renal franchises.

The company in 2026 is seeking approval from global regulators for Casgevy and two cystic fibrosis drugs in younger patients.